International Journal of Clinical Research

Objective To analyze the clinical efficacy and safety of the combination therapy of labetalol and nifedipine in the treatment of gestational hypertension patients. Methods A total of 160 patients with gestational hypertension admitted to our hospital from July 2023 to July 2025 were selected as the study subjects and randomly divided into an observation group and a control group. The control group received monotherapy with labetalol tablets, while the observation group received a combination of nifedipine tablets on this basis. Results After treatment, the levels of SBP, DBP, 24-hour urinary protein quantification, and overall adverse pregnancy outcomes in the observation group were significantly lower than those in the control group (P<0.05). The improvement of various hemorheological indicators in the observation group was significantly greater than that in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The combination of labetalol and nifedipine can effectively control blood pressure in patients with gestational hypertension, demonstrating good clinical application value and safety.

Gestational hypertension; Labetalol; Nifedipine; Blood pressure control; Pregnancy outcome